Friday 1st February 2002 |
Text too small? |
Genesis posted a $9.6 million loss, in line with its 2000 float forecast of $9.1 million. It presented a "bright side" by emphasising it had $47.9 million in cash, down from $61 million a year ago.
"All that demonstrates is that they've burned another $13 million of cash without generating any additional revenue," one analyst commented. Revenue fell $8.7 million to $20 million.
CEO Jim Watson said the company had reached agreement with the US Food and Drug Administration on the next phase of trials of its PVAC psoriasis vaccine.
No comments yet
NZAS Sign Long Term Contracts
Amended - IFT230 Maturity and Exchange for IFT350
Synlait forecast milk price update
Chorus submits 2023 fibre regulatory report
Infratil Infrastructure Bond Exchange Offer opens
May 31st Morning Report
NZAS and Mercury sign long-term agreement, creating opportunity for future investment in renewables
Meridian and NZAS sign long term contracts
ArborGen Holdings Results for Year Ended 31 March 2024
BAI - Full unaudited results to 31 March 2024